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Abstract
Introduction: The aim of the study was to demonstrate interleukin-18 (IL-18)
expression in keratinocytes from psoriatic lesions in comparison to keratinocytes
from uninvolved skin and to study the change of expression after therapeutic
interventions.
Material and methods: This study included 16 patients of different clinical
subtypes of psoriasis. Interleukin-18 gene expression analysis was performed
using real time quantitative PCR. Three biopsies were obtained from each patient.
Two were taken from the lesional psoriatic skin and from uninvolved skin before
starting treatment. A third lesional skin biopsy was taken at the end of 2 months
of treatment. The treatment was in the form of topical steroids or oral systemic
methotrexate. 
Results: Of all 16 studied patients, significantly increased IL-18 expression was
noted in keratinocytes from psoriatic lesions before and after treatment when
compared to keratinocytes from uninvolved skin (p = 0.001 and p = 0.002
respectively). The IL-18 expression in the skin lesions after treatment was
significantly lower than lesional skin before treatment (p = 0.023). In psoriatic
skin lesions of all studied patients IL-18 expression was significantly correlated
with disease duration (r = 0.40 and p = 0.01) and clinical severity of psoriasis
(r = 0.72 and p = 0.001). 
Conclusions: Increased IL-18 expression in keratinocytes from psoriatic lesions
of our patients and its correlation with disease duration and severity supported
the concept of psoriasis as a T cell mediated autoimmune disease. This could
establish therapeutic and preventive approaches for psoriasis that ultimately
lead to improved outcomes for patients. 
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Introduction
Psoriasis is a chronic inflammatory condition which is the result of
persistent stimulation of T cells by antigens of epidermal origin [1]. This
persistent stimulation of T cells is the result of interaction between T cells,
antigen-presenting cells, i.e. Langerhans cells, and antigens, and comprises
the following steps: primary signals (signal 1) including T-cell receptor
stimulation by peptide antigen, costimulation (so-called accessory signals)
(signal 2) and T helper type 1 (Th1) differentiation and proliferation [2].
In 1986, it was proposed that cytokines released by activated 
T-lymphocytes initiate and maintain the psoriatic process by stimulating
keratinocyte proliferation [3]. Since that time it has become clear that,
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upon stimulation, keratinocytes are also able to
secrete an array of different cytokines with a variety
of functional effects on both themselves and other
cell types, including T-lymphocytes [4].
Interleukin (IL)-18 is related to the IL-1 family in
terms of both structure and function. At the
receptor level, the activity of IL-18 takes place
through a signalling chain of a putative IL-18
receptor (IL-18R) complex [5].
Interleukin-18 was first described as an
interferon-γ (IFN-γ) inducing factor. In general, IL-18
induction of IFN-γ is similar to that of IL-12, when
it is a sole cytokine. Interleukin-18 induces low
levels of IFN-γ, but in the presence of costimulants,
IFN-γ production is greatly enhanced [6]. However,
because antibodies to IL-18 also reduced the
hepatotoxicity of endotoxaemia, IL-18 was consi  -
dered to possess other biological properties beyond
that of inducing IFN-γ [7]. Interleukin-18 activates T
cells to synthesize IL-2, GM-CSF, and TNF-α. There
are also reports that IL-18 suppresses the production
of IL-10 and does not induce the production of 
IL-1Ra. In general, the ability of IL-18 to induce
different cytokines depends on the cellular targets
[8]. Flisiak et al. confirmed an association between
plasma IL-18 concentration and psoriasis severity.
Moreover, it was shown that combined measure  -
ment of IL-18 and TGF-β1 in plasma can be
considered as a possible biomarker of psoriasis
activity [9]. Kato et al. indicated that a single
nucleotide polymorphism (SNP) in the promoter of
the IL-18 gene is associated with the presence of
psoriasis, but not atopic dermatitis. This suggests
that the SNP is associated with susceptibility to
psoriasis vulgaris, presumably by affecting the
production of IL-18 [10].
A few studies have analysed IL-18 expression in
psoriasis vulgaris [11-14]. Much less information is
available on the ability of different therapeutic
interventions to modulate ongoing changes in
expression in chronic disorders, especially in
a human disease such as psoriasis. 
The aim of this study was to demonstrate
expression of IL-18 in keratinocytes from psoriatic
lesions in comparison to keratinocytes from non-
lesional skin and to study the change of IL-18
expression after therapeutic interventions. 
Material and methods
This study included 16 patients. The patients
were selected from the outpatient clinic of Benha
University hospital, Al-Haud Al-Marsoud and The
National Research Center, Cairo, Egypt. The patients
included 4 women (25%) and 12 men (75%), and
their ages ranged from 21 to 62 years with a mean
of 40.87 ±13.17 years. They had different clinical
subtypes of psoriasis and exhibited various degrees
of severity. History of present illness included the
onset, course, duration, previous treatment and
date of last topical application or systemic therapy.
Inclusion criteria: those included in the study were
adult psoriatic patients ≥ 18 years old who should
not have received topical therapeutic modality apart
from petrolatum for the last 4 weeks or systemic
therapy for the last 8 weeks. 
Presence or absence of any coexisting non-
cutaneous conditions was established. Three
patients were hypertensive, 3 had psoriatic
arthropathy, 1 had hepatitis C virus (HCV) with
anaemia of chronic disorder type and 1 had
diabetes mellitus with hypertension. A positive
family history was encountered only in one case.
Two patients had upper respiratory tract infections;
cold exposure worsened 5 patients' clinical pre  -
sentation; sweating aggravated 1 patient's con  -
dition; 3 patients had psychogenic factors preci  -
pitating their cases. Only 5 of the studied patients
were not affected by predisposing factors (31.3%). 
The psoriasis area and severity index (PASI) score
sheet was adopted according to Fredriksson and
Pettersson and Marks et al. [15, 16] for all patients
as an indication of degree of severity. In mild cases,
the extent of the disease does not exceed 10, while
in severe cases, the extent of the disease is more
than 30 based on the PASI score [17]. Informed
consent was obtained after complete description
of the study from each participant, according to the
guidelines of the local ethical committee of the
National Research Center.
Two biopsies were taken from each patient in
the first set. The first biopsy was taken from the
lesional psoriatic skin and the second from non-
lesional skin. All patients were subjected to
continuous treatment (in the form of topical
steroids and oral systemic methotrexate) and
follow-up for 2 months. Six patients with moderate
to severe degrees of psoriasis and 2 with
palmoplantar subtype of psoriasis (who did not
respond to topical steroids) received oral systemic
methotrexate. The dosage used was 15 mg per
week in three divided doses taken at 12-h intervals
during a 24-h period with folate supplementation.
Patients receiving systemic methotrexate were
subjected to monitoring liver blood tests monthly.
Eight patients with mild to moderate degrees of
psoriasis were maintained on topical steroid creams
and ointments in the form of betamethasone
dipropionate, twice daily. At the end of the 2-month
course, a third psoriatic lesional skin biopsy was
taken from all patients. 
Tissue processing and preparation
To prevent degradation by intracellular RNases,
tissues were embedded soon after excision in the
RNA stabilizing reagent RNAlater provided by
QIAGEN worldwide companies according to theArch Med Sci 4, August / 2011 715
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manufacturer's instructions to be stored at –70°C
before sample processing. Frozen tissues were not
allowed to thaw during handling to be ready for
quantitative PCR determination of IL-18. Each biopsy
was weighed before processing. Biopsies weighed
up to 20 mg. Efficient disruption and homo  ge  -
nization of the starting material was performed
using a rotor-stator homogenizer.
RNA extraction and complementary (c)DNA
synthesis
Total RNA was extracted using QIA amp RNA
extraction kit provided by QIAGEN worldwide
companies. The concentration and purity of RNA
was determined by measuring its absorbance at
260 nm (A260) and 280 nm (A280) in a UV visible
spectrophotometer. Total RNA (2 μg) was reverse-
transcribed to cDNA with High-Capacity cDNA
Archive kit provided by Applied Biosystems. cDNAs
were stored at –20°C until real-time quantitative
PCR was performed. 
Gene expression quantitation
Real-time quantitative PCR was performed using
the Applied Biosystems Perkin Elmer 7300 sequence
detection system. Primers were IL-18 sense primer
5'-AGG AAT AAA GAT GGC TGC TGA AC-3' and anti-
sense primer 5'-GCT CAC CAC AAC CTC TAC CTC C-3'.
Each PCR reaction (in a 50 μl volume) contained 1×
of TaqMan universal PCR master mix, (2×) 50 nM
to 900 nM of forward primer, 50 nM to 900 nM of
reverse primer, 250 nM of TaqMan probe labelled
with 6-carboxyfluorescein (FAM) and 10 ng to 
100 ng of cDNA. The amplification protocol was 
2 min at 50°C, 10 min at 95°C, then 40 cycles for 
15 s at 95°C and 1 min at 60°C. Relative gene 
ex  pres  sion was determined for each sample.
Amplification of the gene for glyceraldehydes-3-
phosphate dehydro  genase (GAPDH), a constitu  -
tively expressed housekeeping gene, was performed
on all samples. All genes were subsequently
normalized against GAPDH levels. In this study
mRNA levels were expressed in picograms/micro  -
litre (pg/μl).
Statistical analysis
All data were collected from the patient charts
and entered into a computerized spreadsheet. The
fit of the data to the normal distribution was tes  -
ted with Kolmogorov-Smirnov test. Since the
distribution of the data was significantly different
from normal, nonparametric statistics were further
used. Comparisons were made using Mann-
Whitney U, Kruskal Wallis and Wilcoxon signed
ranks tests between variables adjusted for appro  -
priate covariates, and Spearman rank correlation
coefficients were calculated between the assessed
variables. The null hypothesis was rejected with
a two sided p value of < 0.05. All analyses were
performed with SPSS 11.0 for Macintosh (Statistical
Package for the Social Sciences. SPSS Inc., Chicago,
IL, USA).
Results
Demographic and behavioural characteristics of
included patients are presented in Table I. PASI
score used to evaluate the severity of psoriasis
varied from 1.4 to 39 with a mean of 14.96 ±11.82.
According to Ramsay and Lawrence [17], the PASI
score grades in the different subtypes of psoriasis
are demonstrated in Table II. 
Results of quantitative PCR
All patients had detectable levels of IL-18 mRNA
in the uninvolved skin. Table III shows the range,
Characteristics Patients
Age range (mean ± SD) [years] 21-62 (40.875 ±13.17)
Sex (M/F) 12/4
Marital status (+/–) 13/3
Occupation (working/not working) 12/4
Smoking (+/–) 4/12
Duration of disease range  2 months – 14 years
(mean ± SD) [years] 5.88 ±4.50
Family history (+/–) 1/15
Provoking factors (+/–) 11/5
Associated diseases (+/–) 8/8
Table I. Demographic and behavioural characteristics
of patients with psoriasis
Type of psoriasis  PASI score grades
Mild* Moderate*S evere*T otal (%)
Plaque-type 3 2 1 6 (37.5)
Erythrodermic 1 1 (6.3)
Guttate 1 1 (6.3)
Flexural 1 1 (6.3)
Palmoplantar 2 2 (12.5) 
Plaque and gutt  2 2 (12.5)
Plaque and p.p  1 1 (6.3)
Plaque and flex  1 1 (6.3)
Plaque and nails 1 1 (6.3)
Total 7 7 2 16
Table II. The range of the PASI score in the different
types of psoriasis
gutt – guttate, p.p – palmoplantar, flex – flexural 
*According to Ramsay and Lawrence [17]: mild cases – the PASI score
did not exceed 10, moderate cases – the PASI score was > 10 to 30,
severe cases – the PASI score was more than 30716 Arch Med Sci 4, August / 2011
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Variant N Mean ± SD Range Percentiles
25th 50th (Median)7 5 th
All studied patients
IL-18 NL 16 1.10 ±2.14 0.01-7.90 0.0300 0.1850a 1.2675
IL-18 LB 16 3.24 ±5.63 0.17-22.70 0.4900 0.9050 4.9000
IL-18 LA 16 1.78 ±2.72 0.01-8.10 0.2750 0.4600b 1.5250
Patients on TS
IL-18 NL 8 0.26 ±0.44 0.01-1.3 0.014 0.051c 0.337
IL-18 LB 8 1.59 ±2.1 0.17-6.4 0.2275 0.53 2.53
IL-18 LA 8 0.61 ±0.58 0.012-1.6 0.1275 0.415 1.2
Patients on MTX
IL-18 NL 8 1.93 ±2.84 0.012-7.9 0.1625 0.685d 3.775
IL-18 LB 8 4.89 ±7.56 0.49-22.7 0.602 1.385 6.2
IL-18 LA 8 2.95 ±3.52 0.26-8.10 0.3275 0.745 7.26
Table III. Interleukin-18 expression levels in psoriatic patients
IL-18NL – IL-18 in non-lesional skin, IL-18LB – IL-18 in lesional skin before treatment, IL-18LA – IL-18 in lesional skin after treatment, TS – topical
steroids, MTX – methotrexate, asignificantly lower than lesional skin before treatment (p = 0.001) and lesional skin after treatment (p = 0.002),
bsignificantly lower than lesional skin before treatment (p = 0.023), csignificantly lower than lesional skin before treatment (p = 0.012) and after
treatment (p = 0.012), dsignificantly lower than lesional skin before treatment (p = 0.018) 
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Figure 1. The comparisons between median IL-18
expression levels with percentiles in all studied
patients
1 – IL-18 in lesional skin before treatment, 2 – IL-18 in non
lesional skin, 3 – IL-18 in lesional skin after treatment
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Figure 2. Interleukin-18 mean expression levels in
non-lesional and lesional skin (before and after
treatment) in the different subtypes of psoriasis
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mean ± SD and median levels of cytokine gene
expression in each skin biopsy at the different times
before and after receiving medication, whether
topical or systemic. Comparisons between median
IL-18 expression levels with percentiles in all studied
patients are demonstrated in Figure 1.
Significantly lower IL-18 expression in uninvolved
skin than lesional skin before treatment (p = 0.001)
and lesional skin after treatment (p = 0.002) was
demonstrated in all studied patients as one group.
The IL-18 expression in the psoriatic skin lesions
after treatment was significantly lower than lesional
skin before treatment (p = 0.023).
Interleukin-18 mean expression levels in non-
lesional and lesional skin (before and after
treatment) in the different subtypes of psoriasis are
shown in Figure 2. The highest expression level was
noted in plaque and nails clinical subtype of
psoriasis.
Among patients receiving topical steroids,
significantly lower IL-18 expression was detected
in non-lesional skin than lesional skin before
treatment (p  = 0.012) and after treatment 
(p = 0.012). No statistical significance could be
obtained when comparing the change of expression
before and after topical treatment (p = 0.069). 
Individual variations of the IL-18 expression 
levels in non-lesional and lesional skin before and 
after re  ceiv  ing topical steroids are demonstrated in 
Figure 3. Arch Med Sci 4, August / 2011 717
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In patients receiving methotrexate, significantly
lower IL-18 expression was detected in non-lesional
skin than lesional skin before treatment (p = 0.018).
The change of expression levels in lesional skin after
treatment was not statistically significant when
compared to non-lesional skin (p = 0.069) and
lesional skin before treatment (p = 0.12).
Individual variations of the IL-18 expression levels
in non-lesional and lesional skin before and after
receiving systemic methotrexate are demonstrated
in Figure 4. 
In the correlation between IL-18 expression and
different demographic and behavioural charac  -
teristics of the studied patients as one group.
A significant correlation was obtained between 
IL-18 expression levels in psoriatic lesions and the
severity of psoriasis expressed by PASI score 
(r = 0.72 and p = 0.001) and disease duration 
(r = 0.40 and p = 0.01). No significant correlation
could be revealed between IL-18 expression levels
in psoriatic lesions and patients’ age, smoking state,
predisposing factors or coexisting diseases.
Discussion
In the present study our patients with psoriasis
showed significantly increased IL-18 expression in
keratinocytes from psoriatic lesions before and
after receiving medication, whether topical or
systemic, in comparison to keratinocytes from
non-lesional skin. This supports the concept of
psoriasis as a T cell mediated autoimmune
disease. Krueger [18] reported, in his study on
a large series of skin biopsies, increased protein
expression in lesional as opposed to non-lesional
skin samples. Other investigators stated that
lesional skin might be the source of the elevated
plasma levels of IL-18 [19]. In the present work
quantitative PCR using mRNA taken from
uninvolved skin revealed low but detectable levels
of IL-18 mRNA expression. This finding is
consistent with previous studies showing that
human keratinocytes are capable of synthesizing
low levels of IL-18 mRNA even under non-
stimulated conditions [20]. Chang et al. [21] found
that genes specifically modulated in uninvolved
skin play a major role in triggering disease
progression, and in being the first candidate for
early disease diagnosis or development of new
therapies. This finding could allow selection of the
treatment regimen for individual patients. 
In the present study the IL-18 expression in
patients receiving topical steroids was significantly
lower in non-lesional skin than lesional skin before
and after treatment. After 2 months of treatment,
IL-18 expression levels returned back to low values
but not significantly lower than the lesional skin
levels of expression before treatment. In patients
receiving methotrexate non-lesional skin expression
was significantly lower than lesional skin before
treatment. Also the expression levels decreased
after treatment but still not statistically significantly
when compared to lesional skin before treatment.
Otkjaer et al. [22] determined IL-19 and IL-20 in non-
lesional and lesional psoriatic skin after 28 days of
treatment using topical calcipotriol ointment for
mild cases and oral cyclosporine for moderate and
severe cases. They found that in patients treated
with calcipotriol, IL-19 and IL-20 mRNA expression
levels in lesional psoriatic skin were reduced after
14 days, but the reduction became statistically
significant only after 28 days. So the timing for
mRNA expression analysis could affect the degree
of significance. This is further supported by studies
demonstrating a decrease of IL-18 levels after
narrowband UVB therapy together with other
parameters characteristic of the T helper 1 (Th1)
response [23]. Apart from stimulating the Th1
response, IL-18 can regulate the Th2 response
depending on the local cytokine network.
Interleukin-12 enhances IFN-γ production induced
by IL-18, whereas IL-18 alone induces IL- 4 and 
IL-13 production [24].
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Figure 4. Individual variations of the IL-18 expression
levels in non-lesional and lesional skin before and
after receiving systemic methotrexate
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Figure 3. Individual variations of the IL-18 expression
levels in non-lesional and lesional skin before and
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Classic systemic treatments for psoriasis have
not fully met the needs of patients for permanent
improvement. Antibody-based or fusion protein-
based selective targeting of key mediators of
inflammation has been added to the treatment
approaches for psoriasis. Kong et al. and Smeltz
[25, 26] studied IL-18 receptor blocking by using 
1,25-dihydroxyvitamin D in mouse keratinocytes.
They observed that the IL-18 expression level was
decreased synchronously with treatment. Tak et
al. [27] investigated IL-18 binding protein (IL-18
BP) in psoriatic patients and demonstrated that
IL-18 BP neutralizes the activity of IL-18. 
Our study demonstrated that IL-18 expression in
the psoriatic lesions before treatment was
significantly correlated with the severity of psoriasis
and disease duration. No correlation was noted
between IL-18 expression and patients’ age,
smoking status, predisposing factors or coexisting
diseases. Flisiak et al. [9] found a significant
correlation between plasma IL-18 levels and PASI
values. But, they did not find any correlation
between IL-18 concentration in scales and PASI
score. Trinquet et al. [28] studied the influence of
disease duration on gene expression profiles in
psoriasis. They did not reveal any correlation.
However, Craven et al. [29] studied IL-10 in early and
late onset psoriasis and confirmed that IL-10
expression was correlated significantly with disease
duration. Sampogna et al. [30] studied 380 patients
with psoriasis and did not find any significant
difference between older and younger patients
regarding IL-18 levels. On the other hand, Chen et
al. [31] found a statistically significant correlation
between IL-18 expression levels and age with 
p value equal to 0.015. 
In conclusion, based on the increased IL-18
expression levels in psoriatic skin lesions relative
to uninvolved skin, this cytokine appears to be
crucial in the development of the active psoriatic
lesion itself, where it is produced locally by a step
in the evolution of the psoriatic lesion. This could
be supported by its correlation with clinical
severity, disease duration and its expression
reduction after treatment. The decreased
expression after treatment was not to an extent
indicating that the skin had returned to normal.
The small size of the study population and the
heterogeneous group of patients participating 
in the study preclude the drawing of firm
conclusions. Future studies on genes involved 
and array based technologies should allow
confirmation of the results. Also further studies
are recommended to try other lines of treatment
for psoriasis. One of these lines of therapy is to
try r-h IL-18 BP to neutralize IL-18 activity on
a wide scale that may ultimately lead to improved
outcomes for patients. 
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